A 50-year-old glucose patient who had the disease for 2 years, initially took oral hypoglycemic drugs, and her random blood glucose was still as high as 20 mmol/l despite the gradual increase in dosage, and then switched to insulin treatment, which initially failed to bring her blood glucose up to the standard by injecting insulin twice a day. She had to go to the hospital and was hospitalized after consultation. It turned out that she had latent autoimmune diabetes in adults (LADA), which is classified as a subtype of immune-mediated type 1 diabetes. According to epidemiological data, the results of the multicenter survey (LADA china) showed that the prevalence of LADA among Chinese adults with primary type 2 diabetes was 6.1% over the age of 18 and 5.9% over the age of 30; the prevalence was higher in the north than in the south, and the prevalence of LADA in China was at a high level worldwide. Due to the insidious nature of the onset of diabetes, especially LADA, many LADA patients do not come to the clinic until they develop diabetic ketoacidosis. This includes both patients with classical type 1 diabetes and a proportion of patients with type 2 diabetes. Therefore, ketosis onset is not a diagnostic criterion for LADA. Insulin antibodies, including islet cell antibodies (ICA), GADA, IAA, IAA-2A, and ZnT8A are important immunological indicators for the diagnosis of LADA. Among them, GADA appears early and persists for a long time, has a proven clinical predictive value, and together with the fact that it has been standardized in terms of detection, is by far the most sensitive immune indicator recognized for the diagnosis of LADA. It is the responsibility of endocrinologists to screen out these populations and get them on insulin pumps or standardized insulin therapy as soon as possible to maximize and protect the residual pancreatic β-cell function as early as possible, which can delay the occurrence and development of diabetic complications, which is the common goal of our efforts.